DRUG DISCOVERY TODAY - Journal - Bridge of Knowledge

Search

DRUG DISCOVERY TODAY

ISSN:

1359-6446

eISSN:

1878-5832

Disciplines
(Field of Science):

  • information and communication technology (Engineering and Technology)
  • biomedical engineering (Engineering and Technology)
  • medical biology (Medical and Health Sciences )
  • pharmacology and pharmacy (Medical and Health Sciences )
  • medical sciences (Medical and Health Sciences )
  • health sciences (Medical and Health Sciences )
  • biotechnology (Natural sciences)
  • chemical sciences (Natural sciences)

Ministry points: Help

Ministry points - current year
Year Points List
Year 2024 200 Ministry scored journals list 2024
Ministry points - previous years
Year Points List
2024 200 Ministry scored journals list 2024
2023 200 Ministry Scored Journals List
2022 200 Ministry Scored Journals List 2019-2022
2021 200 Ministry Scored Journals List 2019-2022
2020 200 Ministry Scored Journals List 2019-2022
2019 200 Ministry Scored Journals List 2019-2022
2018 45 A
2017 45 A
2016 45 A
2015 45 A
2014 45 A
2013 45 A
2012 45 A
2011 45 A
2010 32 A

Model:

Hybrid

Points CiteScore:

Points CiteScore - current year
Year Points
Year 2022 14.7
Points CiteScore - previous years
Year Points
2022 14.7
2021 14.7
2020 14.1
2019 12.8
2018 13.6
2017 12.3
2016 11.4
2015 11
2014 9.2
2013 11.3
2012 12
2011 12.2

Impact Factor:

Log in to see the Impact Factor.

Filters

total: 3

  • Category
  • Year
  • Options

clear Chosen catalog filters disabled

Catalog Journals

Year 2024
  • Human carnosinases: A brief history, medicinal relevance, and in silico analyses
    Publication

    - DRUG DISCOVERY TODAY - Year 2024

    Carnosine, an endogenous dipeptide, has been found to have a plethora of medicinal properties, such as antioxidant, antiageing, and chelating effects, but with one downside: a short half-life. Carnosinases and two hydrolytic enzymes, which remain enigmatic, are responsible for these features. Hence, here we emphasize why research is valuable for better understanding crucial concepts like ageing, neurodegradation, and cancerogenesis,...

    Full text available to download

Year 2020
  • In silico design of telomerase inhibitors.

    Telomerase is a reverse transcriptase enzyme involved in DNA synthesis at the end of linear chromosomes. Unlike in most other cells, telomerase is reactivated most cancerous cells and, therefore, has become a promising new anticancer target. Despite extensive research, direct telomerase inhibitors have yet not been introduced to the clinics because of the complexity of this enzyme. Structures of this protein from simple organisms...

    Full text available to download

Year 2013

seen 482 times